The Food and Drug Administration yesterday updated its fact sheets for providers and recipients and caregivers for the Johnson & Johnson COVID-19 vaccine, with each revised document outlining a contraindication for the vaccine’s administration to individuals with histories of thrombosis with thrombocytopenia following doses of this or any other adenovirus-vectored COVID-19 vaccine. The updated fact sheets discuss the risk of thrombosis with thrombocytopenia syndrome following vaccination, an ailment that has been observed in males and females 18 years of age and older, with females 30-49 years of age experiencing the highest reporting rate (approximately one case per 100,000 administered doses). Overall, thrombosis with thrombocytopenia syndrome is fatal in approximately one out of seven cases.

Related News Articles

Headline
The Food and Drug Administration yesterday advised people who get a negative result from an at-home COVID-19 antigen test to test themselves again after…
Headline
The Centers for Disease Control and Prevention today released updated guidance to help people protect themselves and others if they are exposed to, sick or…
Headline
Hospital leaders from the AHA’s vaccine confidence initiative share tips for building COVID-19 vaccine confidence. “Getting more Americans vaccinated against…
Blog
This is a confusing time in the public health emergency. Americans are thinking less about COVID-19 on a daily basis and many are eager to move on. But COVID-…
Chairperson's File
Remaining resilient as new variants of COVID-19 spread. Launching mobile health services to help ensure equitable distribution of COVID-19 vaccines. Partnering…
Headline
The Department of Health and Human Services has agreed to purchase 66 million doses of Moderna’s omicron-specific COVID-19 vaccine booster for use this fall if…